ABSTRACT
Case 1
A bone marrow aspirate specimen from a 47-year-old woman with a new diagnosis of B-lymphoblastic leukemia (B-ALL) was sent to the clinical cytogenetics laboratory for conventional cytogenetic and B-ALL fluorescence in situ hybridization (FISH) panel analysis. Of 20 metaphases, 15 were hyperdiploid with trisomies 6 and 14, and tetrasomies 10, 18, and 21 ❚Figure 1A❚. Six of the 15 abnormal metaphases also had a fourth copy of chromosome 14 (tetrasomy 14) . FISH studies revealed tetrasomies 10 and 21, and trisomy/tetrasomy 14 in approximately 85% of interphase cells. The presence of multiple tetrasomies by chromosomes and FISH raised the possibility of "pseudohyperdiploidy" (doubling of a near-haploid or low hypodiploid clone). Chromosomal microarray was performed and revealed multiple whole-chromosome copy-neutral loss of heterozygosity (CN-LOH), thus confirming a doubled near-haploid clone ❚Figure 1B❚. It is critical to distinguish between hyperdiploidy and pseudohyperdiploidy resulting from a doubled near haploid clone, as true hyperdiploidy has a favorable prognosis whereas near haploidy has an unfavorable prognosis.
Case 2
A fresh lymph node specimen from a 14-year-old boy with a high clinical and pathologic suspicion for Burkitt lymphoma was sent to the clinical cytogenetics laboratory for conventional cytogenetic and pediatric Burkitt lymphoma FISH panel analysis. Of five metaphases, four had a complex karyotype with multiple structural and numerical abnormalities, including additional chromatin of undetermined origin attached to 11q23. FISH analysis for MYC, BCL2, BCL6, IGH, IGL, and IGK gene regions were all within normal limits. Considering the new provisional entity Burkitt-like lymphoma with 11q aberration, 1 chromosomal microarray was performed. A 48-Mb gain of 11q13.4-q24.1 and 13.5-Mb loss of 11q24.1-q25 were detected, among other abnormalities including amplification of chromosomal regions 3q29 and 12q21.2 ❚Figure 2❚. These results confirmed the diagnosis of Burkitt-like lymphoma with 11q aberration. 
Consult Questions

Background
Cytogenetic studies play a critical role in the diagnosis, classification, prognosis, and treatment of hematologic neoplasms.
1,2 While conventional chromosome analysis (G-banding) and FISH remain as the primary A B ❚Figure 2❚ A, Whole-genome view of the submitted lymph node specimen. The top plot indicates a 3p deletion, a 6q deletion, an 11q duplication, a terminal 11q deletion, a 12p duplication, and amplification of chromosomal regions 3q29 and 12q21.2. The single nucleotide polymorphism-array tracks (lower plot) are consistent with copy number aberrations and did not identify regions of copy-neutral loss of heterozygosity. B, Enlarged log 2 plot of chromosome 11 indicating a 48-Mb gain of 11q13.4-q24.1 and a 13.5-Mb loss of 11q24. 1-q25. testing methodologies utilized by clinical cytogenetic laboratories for hematologic neoplasms, chromosomal microarray technologies have proven invaluable when used appropriately. Conventional chromosome analysis allows for a genome-wide view of individual neoplastic cells to detect large chromosomal gains and losses, balanced and unbalanced rearrangements, can detect the presence of concurrent unrelated clones, discern one or more subclones, and can detect the presence of emerging clones. However, chromosome analysis requires living, dividing cells, thus paraffin-embedded tissue or other nonviable tissues cannot be evaluated by traditional G-banding studies. Further, when evaluating a standard bone marrow aspirate specimen, neoplastic clones of myeloid origin show preferential rapid division, while clones of lymphoid origin and plasma cell myeloma often fail to grow and those of mature lymphoid origin often do not grow in the absence of CpG-oligodeoxynucleotide (CpG-ODN) stimulation. While a chromosome study allows a genome-wide evaluation, the relative low resolution obtained, particularly metaphase cells harvested from bone marrow aspirates, often precludes the detection of abnormalities less than 10 Mb. In addition, only 20 metaphases are typically analyzed and karyotype analysis can be time consuming and subjective, depending on the clonal complexity, quality of metaphase cells, and the skill of the technologist.
FISH studies for hematologic neoplasms is a fairly objective technique, typically offered as disease-specific panels and, depending on the diagnosis, specific probes are utilized to detect recurrent, clinically significant translocations or inversions, locus-specific copy number aberrations (CNA), and aneuploidies using centromere-specific probes. FISH can be performed on fresh or paraffin-embedded tissue and interphase cells from liquid tumors to rapidly detect clinically significant abnormalities. For example, a suspected case of acute promyelocytic leukemia can have PML-RARA gene fusion testing performed by FISH within 8 hours of specimen receipt, whereas conventional cytogenetic studies would exceed 24 hours. FISH also has the ability to detect cryptic gene rearrangements and CNAs that are undetectable by conventional chromosome analysis, but this analysis is limited to specific, predefined probe targets. In addition, FISH can be used to evaluate many more cells compared to conventional chromosome studies to achieve a greater analytic sensitivity of a specific abnormality. Several disadvantages of FISH exist, including: the inability to determine some structural abnormalities when evaluating interphase cells; the inherent difficulty of interpreting cell signal patterns from fresh or paraffin-embedded tissue due to cut artifact; and the inability to detect chromosomal abnormalities not targeted by FISH probes, including extremely small CNAs for which a reliable FISH probe cannot be designed.
Chromosomal Microarray Technologies
Chromosomal microarray analysis can bridge the gap between genome-wide low-resolution chromosome studies and region-limiting disease-specific targeted FISH panels by providing a genome-wide, high-resolution analysis that does not require viable cells. Historically, patient DNA and a gender-matched normal reference DNA were each labeled with a different fluorophore and allowed to competitively hybridize to oligonucleotide DNA probes that are mapped to known regions throughout the human genome. This process was termed array-based comparative genomic hybridization (aCGH). Following hybridization, an imaging system scans the array chip to determine the amount and relative fluorescence intensity for each oligonucleotide probe. The ratio of fluorescence intensities observed for each oligonucleotide probe is proportional to the ratio of copy numbers present in the patient and reference DNA specimens. More recently developed platforms compare the intensity of fluorophore-labeled patient DNA to a set of reference DNA in silico, thus eliminating the need for competitive hybridization using a reference DNA specimen.
Depending on the number of oligonucleotide probes and their distribution, a genome-wide analysis can be achieved in high-resolution (approximately 5-10 Kb in probe dense regions depending on the microarray platform). Importantly, microarrays can only detect CNAs such as aneuploidies, microdeletions and duplications, chromothripsis, and amplification. The detection of balanced rearrangements, low-level clones with CNAs (present in <20% of neoplastic cells), and copy-neutral loss of heterozygosity (CN-LOH) cannot be achieved using copy number probes. 3 Characterizing the specific chromosomal mechanism generating an unbalanced structural abnormality may also require ancillary studies (eg, performing sequential FISH analysis on a clonal metaphase cell to determine the genomic location of a duplicated chromosomal region).
Single nucleotide polymorphism (SNP) arrays detect a specific genotype at the location of the probe and are compared with an in silico reference. 3 The benefits of SNP arrays include an additional confirmation of CNAs and the ability to detect CN-LOH and some polyploidies, both of which are observed in hematologic neoplasms. Currently, microarray designs for clinical diagnostics use either copy number plus SNP probes, or SNP probes alone. Chromosomal microarray technologies have been utilized for the diagnosis of constitutional disorders since the mid-2000s and are now considered the first-line test in the postnatal evaluation of patients with congenital anomalies not specific to a well-delineated genetic syndrome, apparently nonsyndromic developmental delay/ intellectual disability, and autism spectrum disorder. 4 Despite success in the constitutional setting, the integration of microarray studies into the diagnostic algorithms of hematologic neoplasms has been more gradual, and with good reason. The limitations of microarray analysis, including the inability to detect balanced rearrangements and low-level clones or aberrations (<20% of neoplastic cells), would prevent the detection of clinically significant abnormalities that are commonly observed in many hematologic neoplasms. While variations of microarray techniques have been described including translocation CGH to detect recurrent balanced rearrangements, and manual peak reassignment algorithms to identify clonal evolution, such techniques cannot be relied upon to detect nonrecurrent balanced rearrangements or low-level emerging clones or aberrations. 5, 6 However, microarray studies are ideal for hematologic neoplasms with known recurrent CNAs, CN-LOH, or to further refine breakpoints and identification of gene content of unbalanced rearrangements identified by chromosome studies. This review is intended to highlight those hematologic neoplasms and scenarios when microarray studies would be most beneficial.
Myelodysplastic Syndromes
Cytogenetic studies play an integral role in the evaluation of myelodysplastic syndromes (MDS) and can establish clonality, classification [eg, MDS with isolated del(5q)], prognosis, and guide treatment-related decisions. 1, 2, 7, 8 Approximately 50% of MDS cases yield clones that consist primarily of recurrent CNAs, including -Y, del(5q)/-5, del(7q)/-7, +8, del(11q), del(12p), del(13q)/-13, i(17q), +19, and del(20q).
1 Balanced rearrangements, including inv(3)/t(3;3), t(6;9), and KMT2A (11q23.3) rearrangements, are most frequently observed in therapy-related MDS. 1, 7 The combination of multiple recurrent CNAs with relatively few and infrequently occurring balanced rearrangements makes MDS a suitable neoplasm for microarray studies.
A plethora of studies have been published comparing conventional cytogenetic, FISH, and microarray results in patients with MDS. 13 evaluated 104 MDS patients with conventional chromosome and copy number plus SNP arrays. Similar to the previously described reports, all visible unbalanced abnormalities identified by chromosome analysis were confirmed by copy number plus SNP arrays with the exception of low-level subclones in two cases, and balanced rearrangements in three cases. Of the 66 conventional cytogenetic studies with a normal karyotype, 20 (30%) were abnormal by copy number plus SNP arrays due to CNAs (>5 Mb and <5 Mb) and CN-LOH. In addition, all three cases that failed to yield metaphase cells were interpretable by copy number plus SNP studies.
Approximately half of all karyotypes obtained from MDS cases are normal, a finding that is considered a good prognostic finding according to the Revised International Prognostic Scoring System for MDS (IPSS-R). 1, 7 However, because microarray allows for a genome-wide high-resolution evaluation, interest has been generated for the discovery of new abnormalities unappreciable by conventional cytogenetic analysis. Thiel et al 11 performed aCGH on 107 specimens with normal karyotypes from patients with MDS. Recurrent CNAs were observed in eight patients, including deletions of 4q24 (n = 2), 5q31 (n = 2), 7q22 (n = 3), and 21q22 (n = 2), while 34 additional patients had at least one CNA. Although most of the abnormalities observed were of uncertain clinical significance, these findings may shed light on genetic pathways leading to myeloid neoplasms.
Cell culture failure of bone marrow aspirates or peripheral blood specimens results in the absence of analyzable metaphase cells. Efforts to reveal specific aberrations can be supplemented by interphase FISH, but only a limited number of probes can be utilized depending on the specimen. Arenillas et al 12 evaluated 62 specimens (bone marrow aspirates or peripheral blood) from patients with primary MDS and unsuccessful chromosome studies using SNP arrays. Thirty-one (50%) of 62 specimens harbored aberrations, including 21 with CNAs, eight with CN-LOH, and two with both CNAs and CN-LOH. Clinically significant abnormalities included deletion 5q (n = 10), deletion 7q (n = 4), and a complex karyotype in a single case.
In summary, the application of microarray technologies to MDS samples reliably detected CNAs observed by G-banding, identified clinically significant cryptic CNAs, helped clarify complex karyotypes, and detected CN-LOH when using SNP probes. Importantly, all MDS cases that failed to yield metaphase cells were analyzable by chromosomal microarray studies. The disadvantages consistently addressed in the reviewed studies included the inability to detect balanced rearrangements, to differentiate independent clones, or to reliably detect clone(s) or unbalanced aberrations below 20% to 30% of cells. These disadvantages are important to consider, as the IPSS-R includes inv(3)/t(3;3) and independent clones in the prognostic subgroups. 7 Laboratories that choose to perform microarray without G-banding studies are encouraged to utilize FISH probes for inv(3)/t(3;3), t(6;9), and KMT2A rearrangements.
B-Lymphoblastic Leukemia/Lymphoma
Predominantly observed in childhood, but also affecting adults, B-ALL is a neoplasm of immature B-cell precursor lineage. 1, 14 Cytogenetic studies for B-ALL provide valuable prognostic information that guides treatment-related decisions based on the presence or absence of recurrent genetic abnormalities (BCR-ABL1, KMT2A rearranged, ETV6-RUNX1, hyperdiploidy, hypodiploidy, IGH-IL3, TCF3-PBX1, BCR-ABL1-like, and intrachromosomal amplification of chromosome 21 [iAMP21]). 1, 2, [15] [16] [17] [18] [19] Excluding the balanced rearrangements that are commonly observed in B-ALL, distinguishing hyperdiploidy from pseudohyperdiploidy and identifying the multiple CNAs of prognostic significance make B-ALL another suitable neoplasm for microarray studies.
Hyperdiploidy and hypodiploidy are both recurrent genetic subgroups in B-ALL, and the ability to distinguish between them is critical. While hyperdiploidy (>50-65 chromosomes, usually involving gains of chromosomes 4, 10, 14, 17, and 21) has an excellent prognosis, hypodiploidy (<44 chromosomes) has a poor prognosis. 1, 2, 15, [17] [18] [19] [20] [21] [22] Hypodiploidy can be further subtyped into near haploidy (24-29 chromosomes), low hypodiploidy (33-39 chromosomes), and high hypodiploidy (40-43 chromosomes).
1,21
Nachman et al 21 evaluated 139 patients with B-ALL and hypodiploidy and noted that seven of 25 (28%) low hypodiploid clones, and 25 of 46 (54%) near-haploid clones underwent endoreduplication (doubling of the abnormal clone). Endoreduplication was not observed in any of the high hypodiploid clones (n = 7). The doubling of near-haploid or low hypodiploid clones results in a clone with a chromosome number resembling a hyperdiploid clone, thus the term "pseudohyperdiploid." If this pseudohyperdiploid karyotype is subsequently misclassified as hyperdiploid, a clone with an unfavorable prognosis can erroneously be assigned a favorable prognosis. The presence of a pseudohyperdiploid clone should be suspected when multiple tetrasomies are observed by conventional chromosome analysis ( Figure 1A) . However, obtaining clonal metaphase cells in B-ALL studies can be difficult, and cytogenetic laboratories often rely on FISH to detect recurrent abnormalities. In these instances, the combination of tetrasomies in the presence of monosomies by various FISH probes may serve as a clue. To confirm the presence of a pseudohyperdiploid clone masquerading as a hyperdiploid clone the use of copy number plus SNP studies are warranted. While both copy number and SNP probes detect CNAs, SNP probes reveal multiple whole chromosome CN-LOH, a defining feature that distinguishes pseudohyperdiploidy from true hyperdiploidy ( Figure 1B) . iAMP21, defined here as five or more RUNX1 signals per cell by FISH analysis, is another recurrent genetic subgroup in pediatric B-ALL and is associated with an unfavorable prognosis. 1, 2, [16] [17] [18] [19] 23 While iAMP21 is usually detected by FISH probes that typically identify the ETV6-RUNX1 fusion due to the t(12;21)(p13.2;q22.1), microarray has been shown to be useful in the detection of iAMP21, as demonstrated by Baughn et al 24 in four patients with B-ALL. Harrison et al 23 also reported a higher incidence of ETV6 deletions, RB1 deletions, and P2RY8-CRLF2 fusions (resulting from PAR1 deletion) among iAMP21 patients, all of which are detectable by microarray analysis. In addition, microarray can easily distinguish between iAMP21 and simple gains of chromosome 21.
The presence or absence of specific gene deletions in B-ALL that are often submicroscopic can also have prognostic significance. Deletions of IKZF1 are considered a poor prognostic finding in B-ALL; however, ERG deletions appear to have a favorable prognosis despite the presence or absence of IKZF1 alterations. [15] [16] [17] 19, [25] [26] [27] [28] Additional gene deletions that may modify the prognosis in B-ALL, but require further investigation, include CDKN2A/B, RB1, BTG1, PAX5, ETV6, and PAR1 (resulting in P2RY8-CRLF2 fusions). 2, [15] [16] [17] 19, 27, 28 Baughn et al 24 evaluated 65 patients with B-ALL using copy number plus SNP arrays and the most commonly deleted genes/regions were ETV6 (n = 18, 28%), CDKN2A/B (n = 20, 31%), PAX5 (n = 12, 18%), IKZF1 (n = 8, 12%), PAR1 resulting in CRLF2/ P2RY8 (n = 4, 6%), and RB1 (n = 3, 5%) dependent on the patient's primary cytogenetic abnormality. Importantly, the IKZF1 deletions were variably sized including some partial deletions. Had FISH or multiplex ligation-dependent probe amplification been utilized, these partial deletions might have been incorrectly interpreted as normal. In addition, copy number plus SNP studies revealed on average 5.6 CNAs per case with a normal karyotype (n = 8), including four of eight cases with complete IKZF1 deletions and monoallelic or biallelic CDKN2A/B deletions, and three of eight cases with PAX5 deletions.
Taken together, utilizing microarray studies in B-ALL is appropriate for suspected cases of pseudohyperdiploidy and cases that yield normal chromosome studies. The routine use of microarray studies for all cases of B-ALL in combination with FISH probes targeting recurrent translocations could also be of clinical value, but would need to be determined by individual cytogenetic laboratories.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chromosome aberrations in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are important for risk-stratification purposes.
1,2,29-31 Recurrent CNAs are observed in approximately 80% to 90% of CLL/SLL cases by FISH or microarray studies, including del(11q), +12, del(13q), del(17p), and complex karyotypes. 1, 29, [32] [33] [34] [35] Balanced translocations, including t(14;18) (q32;q21) (IGH/BCL2) and t(14;19)(q32;q13) (IGH/ BCL3), are relatively uncommon in CLL/SLL, accounting for approximately 5% of cases.
1 While these targeted aberrations are readily detectable by FISH, yielding clonal metaphases of mature B-cell neoplasms is difficult and requires the use of B-cell mitogens, including CpGODNs. Similar to MDS, the combination of commonly observed CNAs and a limited number of balanced rearrangements make CLL/SLL an attractive candidate for microarray studies.
The clinical utility of microarray analysis in the setting of CLL/SLL has been well described in the literature. [32] [33] [34] [35] Gunnarsson et al 32 evaluated 369 patients with newly diagnosed CLL using 250K SNP arrays, and 59 of the patients were subsequently evaluated for clonal evolution after 5 to 9 years. Deletions 11q, 13q, 17p (loss of TP53), and trisomy 12 were identified in 70% of the 369 patients evaluated. Heterozygous or homozygous 13q deletions were observed in 55% of patients, followed by trisomy 12 (10.5%), 11q deletions (10%), and 17p deletions (3.5%). No aberrations were detected in 10% of the specimens. Large recurrent regions of CN-LOH were also observed on 13q in 13 patients (10%), 11 of which also had homozygous 13q deletions. Of the 59 patients evaluated for clonal evolution, 20% developed newly acquired recurrent and/or novel CNAs.
Zhang et al 33 compared SNP array and FISH results from 25 patients with CLL. FISH probes targeted specific CNAs to detect MYB (6q23), TP53 (17p13), 13q14.3, and ATM (11q22) deletions and trisomy 12. Overall, 98% concordance was achieved for chromosomal regions targeted by FISH probes and SNP array. Low-level mosaicism for one case each of 13q14.3 deletion and ATM deletion was detected by SNP arrays that were not identified by FISH studies and were below the FISH cutoff level for reporting. Authors attributed this discrepancy to FISH studies being performed on cells from a 24-hour culture, thus skewing the percentage of clonal cells detected. In addition, one case with trisomy 12 in approximately 5% of cells by FISH analysis was not detected by SNP array. Seventy-one additional aberrations were detected by SNP array, although the clinical significance of these findings is currently unclear. Impressively, clonal aberrations were routinely detected at approximately 10% mosaicism using a simulated DNA copy number tool developed from a computer model of mosaicism. However, Gunn et al 34 and Sargent et al 35 only reported aberration detection limits of approximately 25% to 30% using aCGH when compared to FISH studies using similar probe sets.
The routine use of microarray studies for CLL/SLL has been implemented in several clinical cytogenetic laboratories throughout the United States. Although balanced rearrangements are observed in approximately 5% of cases, targeted FISH probes (eg, IGH break apart) could be incorporated into CLL/SLL testing algorithms. Similar to previously discussed hematologic neoplasms, utilizing microarray to detect emerging or low-level aberrations (<20%) in CLL/SLL is not advised. Microarray is well suited to detect 11q aberrations associated with this Burkitt-like lymphoma subtype (Figure 2 ). Unlike FISH studies that are performed on liquid tumors, fresh or paraffin-embedded tissues are dissected thus creating a cut artifact. As a result, differentiating between real CNAs and artificial CNAs can be challenging. Chromosomal microarray studies can be performed on fresh or paraffin-embedded tissue 38 and provide a less-subjective interpretation.
Burkitt-like Lymphoma With 11q Aberration
Conclusion
Chromosomal microarray technologies provide a genome-wide high-resolution analysis that, when utilized appropriately, can provide valuable diagnostic, prognostic, and treatment-related information ❚Table 1❚. Hematologic neoplasms associated with recurrent CNAs and CN-LOH are ideal for microarray studies, while those with recurrent balanced chromosomal aberrations are of limited benefit. In addition, microarray can be performed on fresh or paraffin-embedded tissue or mitotically inactive clones that fail to yield metaphases for chromosome analysis. Chromosomal microarray studies are not appropriate for minimal residual disease monitoring or for the detection of low-level unbalanced abnormalities and emerging clones (<20% of cells). Importantly, we have only reviewed a preselected group of hematologic neoplasms with multiple recurrent CNAs or characteristic aberrations of clinical importance (eg, CN-LOH in B-ALL) that could readily be detected by chromosomal microarray technologies. Other hematologic neoplasms that could potentially benefit from microarray studies, including acute myeloid leukemia and plasma cell myeloma, also require large FISH panels that target balanced rearrangements of prognostic or therapy-related importance.
Lastly, the American College of Medical Genetics and Genomics published technical standards and guidelines in 2013 for the use of microarray analysis in neoplastic disorders, 39 and Schoumans et al 40 subsequently published guidelines in 2016 for the use of microarray analysis in hematologic neoplasms. These guidelines along with the published literature should serve as excellent resources for the continued integration of chromosomal microarray 
